Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch

Democratic control of Congress after the Nov. 3, 2026, midterms has renewed attention to Medicare for All, but the policy faces hurdles including President Trump's veto power through January 2029 and the Senate filibuster. The article identifies Addus HomeCare, Aveanna Healthcare and National Vision as potential beneficiaries if coverage or reimbursement rules change, while stressing that gains are not guaranteed and none depends on the policy becoming law. Recent results were mixed to positive: Addus Q3 revenue rose 7% to $387.7 million, Aveanna Q2 net income increased to $40.3 million but private-duty gross margin fell to 28.9% from 32.5%, and National Vision raised the low end of full-year adjusted EPS guidance to $0.94 from a range starting below that level.

Analysis

The investable signal is reimbursement design, not the election result. A federal program could replace state Medicaid economics with a new fee schedule; broader coverage does not itself imply higher provider rates, and restrictions on provider profits could offset volume gains. That makes AVAH the highest-beta exposure but not necessarily the best beneficiary: its falling private-duty gross margin is a near-term warning that utilization growth is not translating into better unit economics. ADUS has comparatively more support from its existing operating trajectory, though acquisition integration and an already extended share price make chasing a policy premium unattractive. For EYE, the key optionality is explicit inclusion of routine vision and eyewear—not generic universal coverage; without that, the thesis is mostly its operating turnaround. HIMS could face substitution if insurance covers comparable services, but cash-pay convenience and services outside a covered benefit limit the presumed downside. BKD’s private-pay exposure is not automatically impaired: custodial senior care and long-term-care benefits depend on bill language, not the Medicare label.

Days: AVAH’s Nov. 12 report is the nearest fundamental catalyst; a margin update matters more than a breakout. Over 1–3 months, legislative headlines may create sector volatility but are unlikely to resolve reimbursement economics. Over 6–18 months, bill text and funding mechanics are the real catalysts; the veto and Senate hurdles argue against treating enactment as base case. Contrarian view: the article overweights political optionality and underweights execution and benefit-definition risk. Falsify the cautious AVAH view with sustained gross-margin recovery; falsify the EYE policy kicker if proposed coverage excludes eyewear.

Key Decisions for Investors

• Avoid buying ADUS solely on policy headlines. Consider entries on a pullback toward the article’s cited $120 area rather than chasing near highs; reassess if operating momentum or acquisition integration disappoints.
• Treat AVAH as an earnings event, not a pre-report breakout trade. After Nov. 12, require evidence that private-duty gross margin has stabilized or improved before adding; revenue growth without margin repair weakens the reimbursement-leverage thesis.
• Keep EYE on a conditional watchlist: a sustained move through the cited $19–$20 resistance could support a technical turnaround trade, but size the policy component only after bill language confirms eyewear coverage.
• No broad long/short based on the election alone. Monitor draft legislation for provider fee schedules, profit restrictions, home- and community-based care funding, and explicit vision benefits; these terms—not polling or campaign rhetoric—would change relative earnings exposure.